Dougherty & Co Starts Hospira (HSP) at Buy, $42 Target

Dougherty & Co initiated coverage on Hospira (NYSE: HSP) with a Buy rating and $42 price target.

The firm said "we believe remediation efforts are moving in the right direction, including 1) A shake-up of senior management, including key personnel changes in commercial strategy, operations, and quality control. 2) Ongoing deliberations with the FDA on remediation efforts, including the submissions of comprehensive action plans. 3) The hiring of external regulatory and quality control consultants to shore-up cGMP protocols."

For an analyst ratings summary and ratings history on Hospira click here. For more ratings news on Hospira click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
• Leerink Starts Freenome Inc. (FRNM) at Outperform
• Canaccord Starts Galiano Gold (GAU:CN) at Buy